Showing 4471-4480 of 5646 results for "".
- Melling Medical to Distribute Optos Technology to Federal Health Facilitieshttps://modernod.com/news/melling-medical-to-distribute-optos-technology-to-federal-health-facilities/2479175/MellingMedical today announced a new distribution agreement with Optos Inc. to deliver their state-of-the-art equipment to facilities across the federal health care system. “As they work to accommodate growing caseloads, doctors in the federal health system are looking for t
- Belkin Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Secondshttps://modernod.com/news/belkin-laser-completes-enrollment-of-its-glaurious-pivotal-trial-for-glaucoma-laser-treatment-in-seconds/2479174/Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, non-inferiority, observer-masked RCT, a total of 192 patients were randomized across two arms, SLT and DSLT. 6-month follow-up for primary endpoint is ex
- Eversight Names Diane Hollingsworth President/CEOhttps://modernod.com/news/eversight-names-diane-hollingsworth-president-ceo/2479171/Eversight announced that Diane Hollingsworth has been named President/CEO of the nonprofit eye bank network, effective immediately. Ms. Hollingsworth has served as interim President/CEO s
- Ceyeber Announces Advisory Board of World-Renowned Ophthalmologistshttps://modernod.com/news/ceyeber-announces-advisory-board-of-world-renowned-ophthalmologists/2479167/Ceyeber, the developer of implantable intraocular lens technology designed for medical applications and augmented reality, has created a Medical Advisory Board consisting of top ophthalmologists. Ceyeber’s founder and CEO, Robert E. Grant, said, “
- Ocular Therapeutix Fulfills Post-Marketing Approval Requirements for ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-fulfills-post-marketing-approval-requirements-for-resure-sealant/2479164/Ocular Therapeutix has received notification from the FDA confirming it has fulfilled all post-approval study requirements for ReSure Sealant, with a requirement to update the ReSure label reflecting the study results. As a condition for ReSure’s pre-market approval application (PMA) in 2014, the
- Oculis Announces Financing to Advance Topical Therapies for Posterior and Anterior Segmentshttps://modernod.com/news/oculis-announces-financing-to-advance-therapies-for-anterior-segment/2479162/Oculis announced that it has closed an oversubscribed $57 million Series C financing. Proceeds from this financing will accelerate Oculis’ strategy with the aim of delivering key goals in the near-term to drive shareholder value and bring transformative therapies to patients. The
- jCyte Identifies Predictive Biomarker for jCell Therapy in Largest Phase 3 Study for Retinitis Pigmentosahttps://modernod.com/news/jcyte-identifies-predictive-biomarker-for-jcell-therapy-in-largest-phase-3-study-for-retinitis-pigmentosa/2479157/jCyte announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, identifying a predictive biomarker for the upcoming phase 3 study for jCell therapy in retinitis pigmentosa. A detailed analysis by the Cleveland Clinic Cole Eye Institute
- Mallinckrodt Presents Data Evaluating Acthar Gel for the Treatment of Severe Keratitis at ARVOhttps://modernod.com/news/mallinckrodt-presents-data-evaluating-acthar-gel-for-the-treatment-of-severe-keratitis-at-arvo/2479153/Mallinckrodt announced data from its phase 4, multicenter, open-label study to assess the efficacy and safety of Acthar Gel (repository corticotropin injection) in adult patients with treatment-resistant, severe noninfectious keratitis, a disease which involves painful
- The Countess of Wessex Praises Work of Sight-Saving Charity Orbis During Pandemichttps://modernod.com/news/the-countess-of-wessex-praises-work-of-sight-saving-charity-orbis-during-pandemic/2479147/On April 28, 2021, Her Royal Highness The Countess of Wessex spoke in support of international eye care charity Orbis, at a virtual event to discuss delivering eye care to those most in need during the COVID-19 outbreak.
- Adverum Biotechnologies Reports a Adverse Reaction of Hypotony in the INFINITY Trial Evaluating ADVM-022 in Patients With DMEhttps://modernod.com/news/adverum-biotechnologies-reports-a-adverse-reaction-of-hypotony-in-the-infinity-trial-evaluating-advm-022-in-patients-with-dme/2479135/Adverum Biotechnologies announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurr